1
de Jong, Lisa Aniek, Gout-Zwart, Judith J, van den Bosch, Marina, Koops, Mike, Postma, Maarten J
Veröffentlicht in: de Jong , L A , Gout-Zwart , J J , van den Bosch , M , Koops , M & Postma , M J 2019 , ' Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands : a real-world data based cost-effectiveness analysis ' , Journal of Medical Economics , vol. 22 , no. 4 , pp. 306-318 . https://doi.org/10.1080/13696998.2018.1563404;
2019
Veröffentlicht in: de Jong , L A , Gout-Zwart , J J , van den Bosch , M , Koops , M & Postma , M J 2019 , ' Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands : a real-world data based cost-effectiveness analysis ' , Journal of Medical Economics , vol. 22 , no. 4 , pp. 306-318 . https://doi.org/10.1080/13696998.2018.1563404;
2019
2
van Hulst, Marinus, Stevanovic, Jelena, Jacobs, Maartje S, Tieleman, Robert G, Kappelhoff, Bregt, Postma, Maarten J
Veröffentlicht in: van Hulst , M , Stevanovic , J , Jacobs , M S , Tieleman , R G , Kappelhoff , B & Postma , M J 2018 , ' The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands ' , Journal of Medical Economics , vol. 21 , no. 1 , pp. 38-46 . https://doi.org/10.1080/13696998.2017.1372222;
2018
Veröffentlicht in: van Hulst , M , Stevanovic , J , Jacobs , M S , Tieleman , R G , Kappelhoff , B & Postma , M J 2018 , ' The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands ' , Journal of Medical Economics , vol. 21 , no. 1 , pp. 38-46 . https://doi.org/10.1080/13696998.2017.1372222;
2018